MEI Selling General Administrative vs Ebitda Analysis

MEIP Stock

USD 2.55 0.15 5.56%

MEI Pharma financial indicator trend analysis is infinitely more than just investigating MEI Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MEI Pharma is a good investment. Please check the relationship between MEI Pharma Selling General Administrative and its Ebitda accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

Selling General Administrative vs Ebitda

Selling General Administrative vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MEI Pharma Selling General Administrative account and Ebitda. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between MEI Pharma's Selling General Administrative and Ebitda is -0.25. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Ebitda in the same time period over historical financial statements of MEI Pharma, assuming nothing else is changed. The correlation between historical values of MEI Pharma's Selling General Administrative and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of MEI Pharma are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Selling General Administrative i.e., MEI Pharma's Selling General Administrative and Ebitda go up and down completely randomly.

Correlation Coefficient

-0.25

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Selling General Administrative

Ebitda

Most indicators from MEI Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Selling General Administrative is relatively stable compared to the past year. As of 12/16/2024, Enterprise Value Over EBITDA is likely to grow to 0.61, while Issuance Of Capital Stock is likely to drop 0.00.

MEI Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Retained Earnings	Short Term Investments	Short Long Term Debt Total	Non Current Liabilities Total	Property Plant And Equipment Net	Non Current Assets Total	Property Plant And Equipment Gross	Property Plant Equipment	Net Tangible Assets	Good Will	Retained Earnings Total Equity	Capital Surpluse	Intangible Assets
Total Assets		0.76	0.93	0.65	0.25	0.73	0.05	1.0	0.6	0.71	0.66	0.96	1.0	-0.62	0.99	0.13	0.95	0.62	0.61	0.59	0.27	0.64	0.11	-0.74	0.73	0.11
Other Current Liab	0.76		0.85	0.32	0.46	0.86	-0.03	0.73	0.79	0.92	0.82	0.79	0.73	-0.84	0.73	0.46	0.76	0.88	0.88	0.89	0.61	0.32	0.13	-0.86	0.84	0.13
Total Current Liabilities	0.93	0.85		0.42	0.46	0.86	-0.09	0.91	0.73	0.77	0.72	0.95	0.91	-0.72	0.92	0.23	0.93	0.77	0.76	0.75	0.46	0.41	0.0	-0.83	0.79	0.0
Total Stockholder Equity	0.65	0.32	0.42		-0.2	0.2	0.18	0.68	0.2	0.18	0.38	0.42	0.68	-0.27	0.65	0.06	0.41	-0.03	-0.02	-0.06	-0.16	0.97	0.58	-0.34	0.46	0.58
Net Debt	0.25	0.46	0.46	-0.2		0.47	-0.86	0.23	0.58	0.38	0.49	0.34	0.23	-0.54	0.33	0.3	0.31	0.42	0.4	0.47	0.56	-0.16	-0.48	-0.58	0.48	-0.48
Accounts Payable	0.73	0.86	0.86	0.2	0.47		-0.06	0.71	0.74	0.78	0.73	0.8	0.7	-0.76	0.72	0.33	0.77	0.83	0.83	0.83	0.57	0.2	-0.01	-0.81	0.77	-0.01
Cash	0.05	-0.03	-0.09	0.18	-0.86	-0.06		0.05	-0.31	0.06	-0.23	0.03	0.04	0.26	-0.07	-0.21	0.05	0.1	0.12	0.04	-0.31	0.13	0.47	0.29	-0.22	0.47
Cash And Short Term Investments	1.0	0.73	0.91	0.68	0.23	0.71	0.05		0.57	0.67	0.65	0.94	1.0	-0.6	0.99	0.12	0.94	0.58	0.58	0.55	0.24	0.67	0.14	-0.72	0.72	0.14
Common Stock Shares Outstanding	0.6	0.79	0.73	0.2	0.58	0.74	-0.31	0.57		0.72	0.96	0.59	0.58	-0.98	0.57	0.75	0.55	0.62	0.61	0.71	0.9	0.28	0.12	-0.97	0.89	0.12
Other Current Assets	0.71	0.92	0.77	0.18	0.38	0.78	0.06	0.67	0.72		0.71	0.78	0.67	-0.74	0.66	0.38	0.77	0.87	0.87	0.88	0.56	0.18	-0.03	-0.75	0.71	-0.03
Other Stockholder Equity	0.66	0.82	0.72	0.38	0.49	0.73	-0.23	0.65	0.96	0.71		0.6	0.64	-0.99	0.62	0.79	0.56	0.58	0.57	0.65	0.81	0.46	0.29	-0.97	0.92	0.29
Total Liab	0.96	0.79	0.95	0.42	0.34	0.8	0.03	0.94	0.59	0.78	0.6		0.95	-0.6	0.95	0.08	1.0	0.75	0.74	0.71	0.33	0.4	-0.09	-0.72	0.7	-0.09
Total Current Assets	1.0	0.73	0.91	0.68	0.23	0.7	0.04	1.0	0.58	0.67	0.64	0.95		-0.6	0.99	0.12	0.94	0.57	0.57	0.54	0.24	0.67	0.12	-0.72	0.72	0.12
Retained Earnings	-0.62	-0.84	-0.72	-0.27	-0.54	-0.76	0.26	-0.6	-0.98	-0.74	-0.99	-0.6	-0.6		-0.59	-0.8	-0.56	-0.63	-0.63	-0.71	-0.86	-0.34	-0.21	0.97	-0.92	-0.21
Short Term Investments	0.99	0.73	0.92	0.65	0.33	0.72	-0.07	0.99	0.57	0.66	0.62	0.95	0.99	-0.59		0.06	0.94	0.57	0.57	0.54	0.23	0.62	0.03	-0.72	0.73	0.03
Short Long Term Debt Total	0.13	0.46	0.23	0.06	0.3	0.33	-0.21	0.12	0.75	0.38	0.79	0.08	0.12	-0.8	0.06		0.04	0.25	0.24	0.37	0.79	0.18	0.38	-0.65	0.59	0.38
Non Current Liabilities Total	0.95	0.76	0.93	0.41	0.31	0.77	0.05	0.94	0.55	0.77	0.56	1.0	0.94	-0.56	0.94	0.04		0.74	0.73	0.7	0.29	0.39	-0.11	-0.68	0.66	-0.11
Property Plant And Equipment Net	0.62	0.88	0.77	-0.03	0.42	0.83	0.1	0.58	0.62	0.87	0.58	0.75	0.57	-0.63	0.57	0.25	0.74		1.0	0.99	0.58	-0.03	-0.08	-0.66	0.58	-0.08
Non Current Assets Total	0.61	0.88	0.76	-0.02	0.4	0.83	0.12	0.58	0.61	0.87	0.57	0.74	0.57	-0.63	0.57	0.24	0.73	1.0		0.99	0.56	-0.02	-0.06	-0.65	0.58	-0.06
Property Plant And Equipment Gross	0.59	0.89	0.75	-0.06	0.47	0.83	0.04	0.55	0.71	0.88	0.65	0.71	0.54	-0.71	0.54	0.37	0.7	0.99	0.99		0.69	-0.04	-0.06	-0.73	0.63	-0.06
Property Plant Equipment	0.27	0.61	0.46	-0.16	0.56	0.57	-0.31	0.24	0.9	0.56	0.81	0.33	0.24	-0.86	0.23	0.79	0.29	0.58	0.56	0.69		-0.06	0.05	-0.79	0.67	0.05
Net Tangible Assets	0.64	0.32	0.41	0.97	-0.16	0.2	0.13	0.67	0.28	0.18	0.46	0.4	0.67	-0.34	0.62	0.18	0.39	-0.03	-0.02	-0.04	-0.06		0.61	-0.4	0.44	0.61
Good Will	0.11	0.13	0.0	0.58	-0.48	-0.01	0.47	0.14	0.12	-0.03	0.29	-0.09	0.12	-0.21	0.03	0.38	-0.11	-0.08	-0.06	-0.06	0.05	0.61		-0.14	0.21	1.0
Retained Earnings Total Equity	-0.74	-0.86	-0.83	-0.34	-0.58	-0.81	0.29	-0.72	-0.97	-0.75	-0.97	-0.72	-0.72	0.97	-0.72	-0.65	-0.68	-0.66	-0.65	-0.73	-0.79	-0.4	-0.14		-0.93	-0.14
Capital Surpluse	0.73	0.84	0.79	0.46	0.48	0.77	-0.22	0.72	0.89	0.71	0.92	0.7	0.72	-0.92	0.73	0.59	0.66	0.58	0.58	0.63	0.67	0.44	0.21	-0.93		0.21
Intangible Assets	0.11	0.13	0.0	0.58	-0.48	-0.01	0.47	0.14	0.12	-0.03	0.29	-0.09	0.12	-0.21	0.03	0.38	-0.11	-0.08	-0.06	-0.06	0.05	0.61	1.0	-0.14	0.21

Click cells to compare fundamentals

MEI Pharma Account Relationship Matchups

MEI Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	209.7M	174.1M	177.8M	120.8M	41.4M	62.7M
Other Current Liab	6.1M	7.5M	9.9M	11.0M	5.2M	3.9M
Total Current Liabilities	23.3M	30.3M	24.4M	20.3M	8.4M	8.3M
Total Stockholder Equity	78.2M	41.4M	52.4M	24.6M	33.0M	32.7M
Net Debt	(12.3M)	(245K)	(6.1M)	(4.2M)	(3.7M)	(3.9M)
Accounts Payable	2.4M	6.4M	7.9M	6.1M	3.2M	2.2M
Cash	12.3M	8.5M	15.7M	16.9M	3.7M	3.5M
Cash And Short Term Investments	182.6M	153.4M	153.3M	100.7M	38.3M	57.3M
Common Stock Shares Outstanding	4.6M	5.7M	6.3M	6.7M	6.7M	7.0M
Liabilities And Stockholders Equity	209.7M	174.1M	177.8M	120.8M	41.4M	62.7M
Other Current Assets	5.6M	3.8M	7.7M	11.3M	2.4M	1.9M
Other Stockholder Equity	355.5M	369.2M	426.6M	430.6M	421.2M	442.3M
Total Liab	131.5M	132.7M	125.4M	96.2M	8.4M	7.9M
Total Current Assets	208.6M	164.8M	167.1M	107.5M	40.8M	60.9M
Retained Earnings	(277.2M)	(327.8M)	(374.2M)	(406.0M)	(388.2M)	(368.8M)
Short Term Investments	170.3M	144.9M	137.5M	83.8M	34.6M	32.9M
Non Current Liabilities Total	46.3M	20.4M	108.2M	102.4M	101.0M	75.8M
Property Plant And Equipment Net	1.1M	9.3M	10.7M	13.3M	606K	575.7K
Non Current Assets Total	1.1M	9.3M	10.7M	13.3M	606K	575.7K
Property Plant And Equipment Gross	1.1M	9.3M	11.4M	14.3M	2.4M	2.9M
Property Plant Equipment	1.1M	9.3M	10.7M	13.3M	15.3M	16.0M
Net Tangible Assets	78.2M	41.4M	52.4M	24.6M	28.3M	48.6M
Retained Earnings Total Equity	(214.4M)	(231.2M)	(277.2M)	(327.8M)	(295.0M)	(309.8M)
Capital Surpluse	264.9M	279.1M	355.5M	369.2M	424.5M	255.0M
Non Currrent Assets Other	(1.1M)	(9.3M)	(10.7M)	(13.3M)	(12.0M)	(11.4M)
Current Deferred Revenue	14.8M	14.6M	4.8M	317K	364.6K	346.3K
Net Invested Capital	78.2M	41.4M	52.4M	24.6M	33.0M	37.9M
Net Working Capital	185.3M	134.5M	142.7M	87.2M	32.4M	30.8M
Other Liab	108.2M	95.1M	92.2M	64.5M	74.2M	78.2M
Net Receivables	20.4M	7.6M	10.0M	85K	76.5K	72.7K

Pair Trading with MEI Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against MEI Stock

0.55	FLGC	Flora Growth Corp	Pair Corr
0.37	DYAI	Dyadic International	Pair Corr
0.35	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.32	ESPR	Esperion Therapeutics	Pair Corr
0.32	IMAB	I Mab	Pair Corr

The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.

The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC